Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

PRP therapy is more effective and preferred over minoxidil for hair loss.

Baricitinib is effective and safe for treating severe alopecia areata.

Telogen effluvium is common after symptomatic COVID-19, especially in young females, and may be linked to nutritional deficiencies.

Baricitinib is effective and safe for treating severe alopecia areata.

Teledermatology effectively diagnoses and manages non-scarring alopecia remotely.

Androgenetic alopecia is linked to a higher risk of varicose veins, especially in men, but not to major vascular diseases.

QR678 Neo is more effective than PRP for hair growth and quality.

Start low-dose minoxidil gradually, especially for women, to reduce side effects.

Baricitinib is effective for severe alopecia areata but has some side effects.

Systemic minoxidil is generally safe for older adults, but caution is needed for those with heart risks.

Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.

Lighter skin types respond better to narrowband UVB therapy for cutaneous T-cell lymphoma than darker skin types.

Low-dose oral minoxidil helps hair regrowth in COVID-19-related hair loss with few side effects.

Generic topical and transdermal systems usually cause minimal irritation or sensitization.

Systemic treatments like hydroxychloroquine and cyclosporine A help with Lichen Planopilaris and Frontal Fibrosing Alopecia, but ongoing treatment is needed.

CGF injections may safely and effectively promote hair growth in androgenetic alopecia patients.

Most patients with PCOS were prescribed medroxyprogesterone acetate or oral contraceptives, with some experiencing side effects or needing prescription changes.

DCPA commonly affects males' lower legs, showing follicular pustules and white areas.

Finasteride and dutasteride do not significantly change beard thickness in men.

5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.

Frontal fibrosing alopecia mainly affects women over 50, causing hair loss and specific skin changes.

Blood count parameters are not reliable for predicting recurrent implantation failure.

Hair transplants are better for severe hair loss, while scalp micropigmentation suits those with denser hair.

Both PRP and MZT treatments can significantly improve hair growth in patients with androgenetic alopecia.

Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.

Reassurance and counseling are key in managing acute telogen effluvium, with supplements possibly offering a placebo effect.

Bicalutamide is more effective and safer than spironolactone for treating female hair loss.

Topical finasteride/minoxidil is effective but not better than oral finasteride for hair loss.

Pediatric androgenetic alopecia is linked to obesity, family history, hormonal imbalances, and requires personalized treatment including managing comorbidities.

FUE hair transplantation effectively improves hair density and satisfaction in women with androgenetic alopecia.